But the Galaxies Lung-201 trial features notable omissions, plus toxicity.

Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.

Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

Patients' expression of CEACAM5 might hold the key to activity after all.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.

The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.

Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.